FGF9 and melanoma: Indeed, Prahallad and co-workers revealed that SHP-2 knockout clones of SK-Mel888 BRAF(V600E) mutant melanoma cells were unable to confer Vemurafenib resistance, following HGF, fibroblast growth factor 9 (FGF9), and stem cell factor (SCF) exposure [56].